Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus
Tobias Alexander, Lennard Ostendorf, Robert Biesen, Udo Schneider, Gerd R Burmester, Falk Hiepe
Topics & Concepts
MedicineDaratumumabRefractory (planetary science)CD38HydroxychloroquineBelimumabDermatologyInternal medicineImmunologyLupus erythematosusOncologyAntibodyDexamethasoneLenalidomideB-cell activating factorCoronavirus disease 2019 (COVID-19)DiseaseB cellPhysicsGeneticsCD34Stem cellAstrobiologyBiologyInfectious disease (medical specialty)Adenosine and Purinergic SignalingChronic Lymphocytic Leukemia ResearchMonoclonal and Polyclonal Antibodies Research